verapamil and ritonavir

verapamil has been researched along with ritonavir in 44 studies

Research

Studies (44)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (6.82)	18.2507
2000's	19 (43.18)	29.6817
2010's	20 (45.45)	24.3611
2020's	2 (4.55)	2.80

Authors

Authors	Studies
Cvetkovic, M; Fromm, MF; Kim, RB; Leake, B; Wilkinson, GR	1
Choo, EF; Imamura, H; Kim, RB; Leake, B; Wandel, C; Wilkinson, GR; Wood, AJ	1
Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA	1
Adachi, Y; Sugiyama, Y; Suzuki, H	1
Fischer, H; Huwyler, J; Poli, S; Schwab, D; Tabatabaei, A	1
Bruno-Blanch, L; Gálvez, J; García-Domenech, R	1
Thakker, DR; Troutman, MD	1
Dansette, PM; Fontana, E; Poli, SM	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM	1
He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV	1
Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L	1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ	1
Chen, X; Lin, X; Skolnik, S; Wang, J	1
Balani, SK; Gan, LS; Li, P; Lu, C	1
Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A	1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V	1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR	1
Barton, P; Ismair, M; Jupp, R; Riley, RJ; Soars, MG	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Artursson, P; Mateus, A; Matsson, P	1
Andréola, ML; Bailly, F; Calmels, C; Christ, F; Cotelle, P; Debyser, Z; Lion, C; Suchaud, V	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Andréola, ML; Bailly, F; Billamboz, M; Christ, F; Cotelle, P; Debyser, Z; Lion, C; Suchaud, V	1
Alex, R; Alsenz, J; Steffen, H	1
Back, DJ; Eagling, VA; Profit, L	1
Daily, JP; Fahey, JM; Greenblatt, DJ; Perloff, MD; von Moltke, LL	1
Raffi, F	1
Blom-Roosemalen, MC; Breimer, DD; de Boer, AG; Nabulsi, L; van der Sandt, IC; Voorwinden, HH; Vos, CM	1
Cauda, R; Leone, G; Lucia, MB; Rutella, S	1
Greenblatt, DJ; Perloff, MD; Shader, RI; Störmer, E; von Moltke, LL	1
Kunta, JR; Lee, HS; Lee, YH; Perry, BA; Sinko, PJ; Sutyak, JP	1
Greenblatt, DJ; Perloff, MD; von Moltke, LL	1
Bertelsen, KM; Greenblatt, DJ; von Moltke, LL	1
Daveluy, A; Girodet, PO; Haramburu, F; Miremont-Salamé, G; Molimard, M; Moore, N; Raignoux, C	1
Kwatra, D; Luo, S; Mitra, AK; Pal, D; Paturi, KD; Shah, SJ	1
du Plooy, M; Rheeders, M; Viljoen, M	1
Bellavance, E; Bourg, S; Duan, J; Garneau, M; Ribadeneira, MD; Rioux, N	1
Aa, JY; Cao, B; Ge, C; Gu, RR; Li, MJ; Liu, CX; Liu, LS; Ma, T; Mao, Y; Shi, J; Sun, RB; Wang, GJ; Wang, XW; Wu, XL; Xia, WJ; Xiao, WJ; Yu, XY; Zha, WB; Zheng, T; Zhou, J	1
Burhenne, J; Fricker, G; Mylius, P; Schubert, R; Weinheimer, M	1
Cemillán-Fernández, CA; Domingo-García, J; Fouz-Ruiz, D; Gómez-Enjuto, S; Hernando-Requejo, V; Lapeña-Motilva, J; Ogando-Durán, G; Rodríguez-García, E	1
Haque, OI; Hussain, S; Mahar, S; Sloane, P	1

Reviews

3 review(s) available for verapamil and ritonavir

Article	Year
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Current drug metabolism, 2005, Volume: 6, Issue:5 Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic	2005
Membrane transporters in drug development. Nature reviews. Drug discovery, 2010, Volume: 9, Issue:3 Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs	2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

41 other study(ies) available for verapamil and ritonavir

Article	Year
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug metabolism and disposition: the biological fate of chemicals, 1999, Volume: 27, Issue:8 Topics: Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Caco-2 Cells; Carrier Proteins; Genes, MDR; HeLa Cells; Histamine H1 Antagonists; Humans; LLC-PK1 Cells; Mice; Rats; Swine; Terfenadine; Tissue Distribution; Transfection; Vaccinia virus	1999
Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug metabolism and disposition: the biological fate of chemicals, 2000, Volume: 28, Issue:6 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Brain; Caco-2 Cells; Dibenzocycloheptenes; HIV Protease Inhibitors; Humans; Inhibitory Concentration 50; Male; Mice; Quinolines; Testis	2000
Rational use of in vitro P-glycoprotein assays in drug discovery. The Journal of pharmacology and experimental therapeutics, 2001, Volume: 299, Issue:2 Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera	2001
Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharmaceutical research, 2001, Volume: 18, Issue:12 Topics: Adenosine Triphosphate; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blood-Brain Barrier; Caco-2 Cells; Cell Membrane Permeability; Dose-Response Relationship, Drug; Humans; Hydrolysis; LLC-PK1 Cells; Male; Mice; Mice, Knockout; Models, Biological; Pharmaceutical Preparations; Swine; Tissue Distribution; Transfection	2001
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. Journal of medicinal chemistry, 2003, Apr-24, Volume: 46, Issue:9 Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Drug Evaluation, Preclinical; Fluoresceins; Fluorescent Dyes; Humans; Indicators and Reagents; Mice; Models, Molecular; Rhodamines; Species Specificity; Swine	2003
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity. Bioorganic & medicinal chemistry letters, 2003, Aug-18, Volume: 13, Issue:16 Topics: Anticonvulsants; Computer Simulation; Databases, Factual; Discriminant Analysis; Drug Design; Molecular Structure; Quantitative Structure-Activity Relationship	2003
Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharmaceutical research, 2003, Volume: 20, Issue:8 Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blotting, Western; Cells, Cultured; Diffusion; Humans; Intestinal Absorption; Intestinal Mucosa; Models, Biological; Permeability; Pharmaceutical Preparations; Pharmacokinetics	2003
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). Journal of medicinal chemistry, 2008, Jun-12, Volume: 51, Issue:11 Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship	2008
First-principle, structure-based prediction of hepatic metabolic clearance values in human. European journal of medicinal chemistry, 2009, Volume: 44, Issue:4 Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations	2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics	2010
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model. Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:2 Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity	2011
A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors. Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:6 Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Inhibitory Concentration 50; Microsomes, Liver; Time Factors	2011
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites. Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:7 Topics: Glutathione; Pharmacology; Sulfur Radioisotopes	2011
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, 2011, Volume: 16, Issue:15-16 Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration	2011
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection	2012
The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:8 Topics: Cell Line; Drug Discovery; Humans; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters	2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
A high-throughput cell-based method to predict the unbound drug fraction in the brain. Journal of medicinal chemistry, 2014, Apr-10, Volume: 57, Issue:7 Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization	2014
Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors. Journal of medicinal chemistry, 2014, Jun-12, Volume: 57, Issue:11 Topics: Aryl Hydrocarbon Hydroxylases; Cell Line, Tumor; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Resistance, Viral; HIV Integrase Inhibitors; HIV-1; Humans; Isoquinolines; Molecular Docking Simulation; Mutation; Structure-Activity Relationship	2014
2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4. European journal of medicinal chemistry, 2016, Jul-19, Volume: 117 Topics: Alkylation; Anti-HIV Agents; Cell Line; Drug Resistance, Viral; HIV Integrase Inhibitors; Humans; Isoquinolines; Structure-Activity Relationship	2016
Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharmaceutical research, 1998, Volume: 15, Issue:3 Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Biological Transport; Caco-2 Cells; Calcium Channel Blockers; Cyclosporine; HIV Protease Inhibitors; Humans; Immunosuppressive Agents; Intestinal Absorption; Ritonavir; Saquinavir; Verapamil; Vinblastine	1998
Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS (London, England), 1999, Sep-10, Volume: 13, Issue:13 Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Flow Cytometry; Fluorescent Dyes; HIV Protease Inhibitors; Humans; Indinavir; Lymphocytes; Nelfinavir; Rhodamine 123; Ritonavir; Saquinavir; Temperature; Verapamil	1999
Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS (London, England), 2000, Jun-16, Volume: 14, Issue:9 Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamates; Cell Line, Transformed; Colonic Neoplasms; Drug Resistance, Multiple; Furans; Gene Expression Regulation, Neoplastic; HIV Protease Inhibitors; Humans; Indinavir; Ivermectin; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; Tumor Cells, Cultured; Verapamil; Vinblastine	2000
[Resistance to protease inhibitors: the role of the MDR gene]. Presse medicale (Paris, France : 1983), 2000, Dec-02, Volume: 29, Issue:37 Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Bacterial Proteins; Biological Availability; Calcium Channel Blockers; Carrier Proteins; Drug Resistance, Microbial; Gene Expression Regulation; Humans; K562 Cells; Membrane Transport Proteins; Nelfinavir; Protease Inhibitors; Ritonavir; Verapamil	2000
Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier. AIDS (London, England), 2001, Mar-09, Volume: 15, Issue:4 Topics: Animals; Astrocytes; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Transport, Active; Blood-Brain Barrier; Caco-2 Cells; Carbamates; Cattle; Cell Line, Transformed; Cells, Cultured; Coculture Techniques; Cyclosporins; Dibenzocycloheptenes; Endothelium, Vascular; Furans; HIV Protease Inhibitors; Humans; Indinavir; LLC-PK1 Cells; Multidrug Resistance-Associated Proteins; Probenecid; Quinolines; Rats; Rats, Wistar; Ritonavir; Sulfonamides; Swine; Verapamil	2001
HIV protease inhibitors reduce IL-2 release from normal human phytohaemagglutinin-activated T cells. AIDS (London, England), 2001, Nov-23, Volume: 15, Issue:17 Topics: Calcium Channel Blockers; HIV Protease Inhibitors; Humans; Indinavir; Interleukin-2; Lymphocyte Activation; Mitogens; Phytohemagglutinins; Ritonavir; Saquinavir; T-Lymphocytes; Verapamil	2001
Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. British journal of pharmacology, 2001, Volume: 134, Issue:8 Topics: Adenocarcinoma; Anthracenes; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Blotting, Western; Caco-2 Cells; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Multiple; Humans; Hypericum; Image Processing, Computer-Assisted; Microscopy, Fluorescence; Perylene; Protein Kinase C; Rhodamine 123; Ritonavir; Time Factors; Tumor Cells, Cultured; Verapamil	2001
Differentiation of gut and hepatic first-pass effect of drugs: 1. Studies of verapamil in ported dogs. Pharmaceutical research, 2001, Volume: 18, Issue:12 Topics: Animals; Area Under Curve; Calcium Channel Blockers; Dogs; Duodenum; Injections, Intravenous; Intestinal Absorption; Liver; Male; Portal Vein; Ritonavir; Time Factors; Verapamil	2001
Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir. Journal of clinical pharmacology, 2002, Volume: 42, Issue:11 Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Caco-2 Cells; Chromatography, High Pressure Liquid; Depression, Chemical; Drug Interactions; Drug Stability; Fluorometry; Histamine H1 Antagonists; Humans; In Vitro Techniques; Kinetics; Rhodamines; Ritonavir; Terfenadine; Time Factors; Verapamil	2002
Apparent active transport of MDMA is not mediated by P-glycoprotein: a comparison with MDCK and Caco-2 monolayers. Biopharmaceutics & drug disposition, 2006, Volume: 27, Issue:5 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Cell Line; Dogs; Humans; Indomethacin; N-Methyl-3,4-methylenedioxyamphetamine; Probenecid; Progesterone; Propionates; Quinolines; Rhodamine 123; Ritonavir; Verapamil	2006
Drug interactions between inhaled corticosteroids and enzymatic inhibitors. European journal of clinical pharmacology, 2009, Volume: 65, Issue:7 Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenal Insufficiency; Adult; Aged; Anti-Asthmatic Agents; Asthma; Child; Cushing Syndrome; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Diltiazem; Dose-Response Relationship, Drug; Drug Interactions; Female; HIV Protease Inhibitors; Humans; Incidence; Itraconazole; Male; Middle Aged; Retrospective Studies; Ritonavir; Verapamil	2009
Effect of HEPES buffer on the uptake and transport of P-glycoprotein substrates and large neutral amino acids. Molecular pharmaceutics, 2010, Apr-05, Volume: 7, Issue:2 Topics: Adenosine Triphosphate; Amino Acids, Neutral; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Cell Line; Cell Membrane Permeability; Cyclosporine; Dogs; Glutamic Acid; HEPES; Humans; Lopinavir; Phenylalanine; Pyrimidinones; Ritonavir; Verapamil	2010
Evidence for time-dependent interactions between ritonavir and lopinavir/ritonavir plasma levels following P-glycoprotein inhibition in Sprague-Dawley rats. Biological & pharmaceutical bulletin, 2011, Volume: 34, Issue:1 Topics: Animals; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Blockers; Drug Administration Schedule; Lopinavir; Male; Pyrimidinones; Rats; Rats, Sprague-Dawley; Ritonavir; Verapamil	2011
Assessment of CYP3A-mediated drug-drug interaction potential for victim drugs using an in vivo rat model. Biopharmaceutics & drug disposition, 2013, Volume: 34, Issue:7 Topics: Animals; Buspirone; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Ketoconazole; Male; Microsomes, Liver; Rats; Rats, Wistar; Ritonavir; Verapamil	2013
Pharmacokinetic interactions between 20(S)-ginsenoside Rh2 and the HIV protease inhibitor ritonavir in vitro and in vivo. Acta pharmacologica Sinica, 2013, Volume: 34, Issue:10 Topics: Acridines; Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Chromatography, Liquid; Dogs; Dose-Response Relationship, Drug; Drug Interactions; Ginsenosides; HIV Protease Inhibitors; Humans; Injections, Intravenous; Madin Darby Canine Kidney Cells; Male; Mass Spectrometry; Rats; Rats, Wistar; Ritonavir; Tetrahydroisoquinolines; Tissue Distribution; Verapamil	2013
The application of P-gp inhibiting phospholipids as novel oral bioavailability enhancers - An in vitro and in vivo comparison. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2017, Oct-15, Volume: 108 Topics: Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Biological Transport; Caco-2 Cells; Drug Delivery Systems; Humans; Intestinal Absorption; Male; Phosphatidylcholines; Phospholipids; Polysorbates; Rats, Wistar; Rhodamine 123; Ritonavir; Surface-Active Agents; Verapamil	2017
Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient. Seizure, 2020, Volume: 80 Topics: Aged; Anemia; Anticoagulants; Anticonvulsants; Antiviral Agents; Betacoronavirus; Calcium Channel Blockers; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Enzyme Inhibitors; Humans; Hydroxychloroquine; Lopinavir; Lymphopenia; Male; Pandemics; Pneumonia, Viral; Posterior Leukoencephalopathy Syndrome; Ritonavir; SARS-CoV-2; Status Epilepticus; Verapamil	2020
Pharmacokinetic interaction between verapamil and ritonavir-boosted nirmatrelvir: implications for the management of COVID-19 in patients with hypertension. BMJ case reports, 2023, Jan-13, Volume: 16, Issue:1 Topics: Bradycardia; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Ritonavir; SARS-CoV-2; Verapamil	2023